Compare Abeona Therapeutics Inc (ABEO) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares MSCI China ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while iShares MSCI China ETF trades at $52.88. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | MCHI | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.23 | $66.99 |
52-Week Low | $4.17 | $50.48 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MCHI trades at $52.02, up 2.18% today, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. The stock faces resistance at $52. Recent news highlights China's AI and export-driven factory rebound, which could benefit broad China ETFs like MCHI, but structural headwinds and value trap risks persist according to some analysts.
The outlook remains cautious due to mixed technicals and macroeconomic uncertainties. Opportunities exist if China's tech and manufacturing recovery accelerates, but risks include U.S.-China tensions, deflationary pressures, and potential regulatory changes. Investors should weigh the ETF's exposure to China's cyclical sectors against its attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
